CA2085897A1 - Virus variant non pathogene - Google Patents

Virus variant non pathogene

Info

Publication number: CA2085897A1
Authority: CA; Canada
Prior art keywords: hiv; nonpathogenic; virus; variant; strain
Prior art date: 1990-06-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002085897A

Other languages

English (en)

Inventor

George Pieczenik

Michael Scolaro

Roy Durham

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

IMMUVAX

Original Assignee

IMMUVAX

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-06-19

Filing date

1991-06-19

Publication date

1991-12-20

1991-06-19 Application filed by IMMUVAX filed Critical IMMUVAX

1991-12-20 Publication of CA2085897A1 publication Critical patent/CA2085897A1/fr

Status Abandoned legal-status Critical Current

Links

241000700605 Viruses Species 0.000 title claims abstract description 106
230000001717 pathogenic effect Effects 0.000 claims abstract description 46
208000030507 AIDS Diseases 0.000 claims abstract description 20
230000002860 competitive effect Effects 0.000 claims abstract description 16
241000725303 Human immunodeficiency virus Species 0.000 claims description 96
238000000034 method Methods 0.000 claims description 40
230000035772 mutation Effects 0.000 claims description 38
210000004027 cell Anatomy 0.000 claims description 37
238000012360 testing method Methods 0.000 claims description 37
239000002773 nucleotide Substances 0.000 claims description 28
125000003729 nucleotide group Chemical group 0.000 claims description 28
230000007918 pathogenicity Effects 0.000 claims description 20
230000003993 interaction Effects 0.000 claims description 19
208000024891 symptom Diseases 0.000 claims description 19
230000008859 change Effects 0.000 claims description 17
201000010099 disease Diseases 0.000 claims description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
241000282414 Homo sapiens Species 0.000 claims description 13
230000003902 lesion Effects 0.000 claims description 13
210000000601 blood cell Anatomy 0.000 claims description 11
229960005486 vaccine Drugs 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 10
230000003044 adaptive effect Effects 0.000 claims description 9
230000012010 growth Effects 0.000 claims description 7
238000012216 screening Methods 0.000 claims description 7
101710132601 Capsid protein Proteins 0.000 claims description 5
230000003053 immunization Effects 0.000 claims description 5
230000024932 T cell mediated immunity Effects 0.000 claims description 4
230000028993 immune response Effects 0.000 claims description 4
230000001131 transforming effect Effects 0.000 claims description 2
206010011831 Cytomegalovirus infection Diseases 0.000 claims 3
238000010367 cloning Methods 0.000 claims 2
238000012258 culturing Methods 0.000 claims 2
239000003085 diluting agent Substances 0.000 claims 2
238000010353 genetic engineering Methods 0.000 abstract 1
238000011081 inoculation Methods 0.000 description 27
208000015181 infectious disease Diseases 0.000 description 21
210000004369 blood Anatomy 0.000 description 18
239000008280 blood Substances 0.000 description 18
108090000623 proteins and genes Proteins 0.000 description 18
108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
210000001744 T-lymphocyte Anatomy 0.000 description 15
230000002238 attenuated effect Effects 0.000 description 15
101710147327 Calcineurin B homologous protein 1 Proteins 0.000 description 14
101710205625 Capsid protein p24 Proteins 0.000 description 14
101710177166 Phosphoprotein Proteins 0.000 description 14
101710149279 Small delta antigen Proteins 0.000 description 14
102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 14
102000004169 proteins and genes Human genes 0.000 description 14
230000004044 response Effects 0.000 description 14
210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 12
239000000427 antigen Substances 0.000 description 12
102000036639 antigens Human genes 0.000 description 12
108091007433 antigens Proteins 0.000 description 12
230000001976 improved effect Effects 0.000 description 12
230000003612 virological effect Effects 0.000 description 12
150000002500 ions Chemical class 0.000 description 11
108020004414 DNA Proteins 0.000 description 9
241000726306 Irus Species 0.000 description 9
230000036039 immunity Effects 0.000 description 9
238000001262 western blot Methods 0.000 description 9
230000008901 benefit Effects 0.000 description 8
238000003752 polymerase chain reaction Methods 0.000 description 8
230000007103 stamina Effects 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
230000000694 effects Effects 0.000 description 7
241000274177 Juniperus sabina Species 0.000 description 6
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 6
230000036541 health Effects 0.000 description 6
230000016784 immunoglobulin production Effects 0.000 description 6
230000006872 improvement Effects 0.000 description 6
230000010076 replication Effects 0.000 description 6
230000005951 type IV hypersensitivity Effects 0.000 description 6
208000027930 type IV hypersensitivity disease Diseases 0.000 description 6
230000001018 virulence Effects 0.000 description 6
230000036642 wellbeing Effects 0.000 description 6
206010042566 Superinfection Diseases 0.000 description 5
238000012544 monitoring process Methods 0.000 description 5
244000052769 pathogen Species 0.000 description 5
230000009467 reduction Effects 0.000 description 5
238000011282 treatment Methods 0.000 description 5
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 4
241000991587 Enterovirus C Species 0.000 description 4
241000282412 Homo Species 0.000 description 4
208000008771 Lymphadenopathy Diseases 0.000 description 4
208000000474 Poliomyelitis Diseases 0.000 description 4
108020004566 Transfer RNA Proteins 0.000 description 4
230000002596 correlated effect Effects 0.000 description 4
230000000875 corresponding effect Effects 0.000 description 4
230000006378 damage Effects 0.000 description 4
230000007812 deficiency Effects 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
230000006870 function Effects 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
208000018555 lymphatic system disease Diseases 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
108020004707 nucleic acids Proteins 0.000 description 4
102000039446 nucleic acids Human genes 0.000 description 4
150000007523 nucleic acids Chemical class 0.000 description 4
238000012809 post-inoculation Methods 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
208000006820 Arthralgia Diseases 0.000 description 3
101710094648 Coat protein Proteins 0.000 description 3
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 3
108010050904 Interferons Proteins 0.000 description 3
102000014150 Interferons Human genes 0.000 description 3
101710125418 Major capsid protein Proteins 0.000 description 3
101710141454 Nucleoprotein Proteins 0.000 description 3
101710083689 Probable capsid protein Proteins 0.000 description 3
239000012980 RPMI-1640 medium Substances 0.000 description 3
101800001690 Transmembrane protein gp41 Proteins 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
229940079322 interferon Drugs 0.000 description 3
QVDXUKJJGUSGLS-LURJTMIESA-N methyl L-leucinate Chemical compound COC(=O)[C@@H](N)CC(C)C QVDXUKJJGUSGLS-LURJTMIESA-N 0.000 description 3
230000003472 neutralizing effect Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
230000009897 systematic effect Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
230000007704 transition Effects 0.000 description 3
230000014616 translation Effects 0.000 description 3
230000004584 weight gain Effects 0.000 description 3
235000019786 weight gain Nutrition 0.000 description 3
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
241000784713 Cupido Species 0.000 description 2
208000031886 HIV Infections Diseases 0.000 description 2
208000037357 HIV infectious disease Diseases 0.000 description 2
108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
102100040018 Interferon alpha-2 Human genes 0.000 description 2
108010079944 Interferon-alpha2b Proteins 0.000 description 2
206010030216 Oesophagitis Diseases 0.000 description 2
206010033645 Pancreatitis Diseases 0.000 description 2
208000017442 Retinal disease Diseases 0.000 description 2
206010038923 Retinopathy Diseases 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
QXAITBQSYVNQDR-UHFFFAOYSA-N amitraz Chemical compound C=1C=C(C)C=C(C)C=1N=CN(C)C=NC1=CC=C(C)C=C1C QXAITBQSYVNQDR-UHFFFAOYSA-N 0.000 description 2
230000002547 anomalous effect Effects 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
102000015736 beta 2-Microglobulin Human genes 0.000 description 2
108010081355 beta 2-Microglobulin Proteins 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
230000006866 deterioration Effects 0.000 description 2
208000006881 esophagitis Diseases 0.000 description 2
206010016256 fatigue Diseases 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
230000036449 good health Effects 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
230000009610 hypersensitivity Effects 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000036737 immune function Effects 0.000 description 2
230000002147 killing effect Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
244000045947 parasite Species 0.000 description 2
239000002245 particle Substances 0.000 description 2
231100000255 pathogenic effect Toxicity 0.000 description 2
208000033808 peripheral neuropathy Diseases 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
102000006688 ral GTP-Binding Proteins Human genes 0.000 description 2
108010087304 ral GTP-Binding Proteins Proteins 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
230000001568 sexual effect Effects 0.000 description 2
241000894007 species Species 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000013519 translation Methods 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
230000035899 viability Effects 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
HRANPRDGABOKNQ-ORGXEYTDSA-N (1r,3r,3as,3br,7ar,8as,8bs,8cs,10as)-1-acetyl-5-chloro-3-hydroxy-8b,10a-dimethyl-7-oxo-1,2,3,3a,3b,7,7a,8,8a,8b,8c,9,10,10a-tetradecahydrocyclopenta[a]cyclopropa[g]phenanthren-1-yl acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1[C@H](O)C[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 HRANPRDGABOKNQ-ORGXEYTDSA-N 0.000 description 1
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
101150034533 ATIC gene Proteins 0.000 description 1
108020005098 Anticodon Proteins 0.000 description 1
208000031504 Asymptomatic Infections Diseases 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
206010007134 Candida infections Diseases 0.000 description 1
241000581364 Clinitrachus argentatus Species 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
206010010144 Completed suicide Diseases 0.000 description 1
241000518994 Conta Species 0.000 description 1
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
101710116602 DNA-Binding protein G5P Proteins 0.000 description 1
101100012466 Drosophila melanogaster Sras gene Proteins 0.000 description 1
101100346656 Drosophila melanogaster strat gene Proteins 0.000 description 1
101150039033 Eci2 gene Proteins 0.000 description 1
208000032274 Encephalopathy Diseases 0.000 description 1
102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
241000709739 Enterobacteria phage f2 Species 0.000 description 1
241000709744 Enterobacterio phage MS2 Species 0.000 description 1
101710091045 Envelope protein Proteins 0.000 description 1
101000701698 Escherichia phage P2 Spike protein Proteins 0.000 description 1
101150048348 GP41 gene Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
238000006165 Knowles reaction Methods 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
208000005647 Mumps Diseases 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
240000008881 Oenanthe javanica Species 0.000 description 1
208000007027 Oral Candidiasis Diseases 0.000 description 1
238000002944 PCR assay Methods 0.000 description 1
206010033647 Pancreatitis acute Diseases 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
240000007643 Phytolacca americana Species 0.000 description 1
235000009074 Phytolacca americana Nutrition 0.000 description 1
208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
101710188315 Protein X Proteins 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
101710162453 Replication factor A Proteins 0.000 description 1
101710176758 Replication protein A 70 kDa DNA-binding subunit Proteins 0.000 description 1
206010038910 Retinitis Diseases 0.000 description 1
101710176276 SSB protein Proteins 0.000 description 1
206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
101710126859 Single-stranded DNA-binding protein Proteins 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
102000039471 Small Nuclear RNA Human genes 0.000 description 1
108020004688 Small Nuclear RNA Proteins 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
241000287411 Turdidae Species 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
108010015780 Viral Core Proteins Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
201000003229 acute pancreatitis Diseases 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
230000027455 binding Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
238000004820 blood count Methods 0.000 description 1
244000309466 calf Species 0.000 description 1
201000003984 candidiasis Diseases 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
230000006727 cell loss Effects 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000024203 complement activation Effects 0.000 description 1
201000003740 cowpox Diseases 0.000 description 1
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
208000028327 extreme fatigue Diseases 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
229960002963 ganciclovir Drugs 0.000 description 1
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
239000000499 gel Substances 0.000 description 1
210000001983 hard palate Anatomy 0.000 description 1
201000000615 hard palate cancer Diseases 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
230000000652 homosexual effect Effects 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
208000006575 hypertriglyceridemia Diseases 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000007775 late Effects 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000000207 lymphocyte subset Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
208000010805 mumps infectious disease Diseases 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
230000036438 mutation frequency Effects 0.000 description 1
VOVZXURTCKPRDQ-CQSZACIVSA-N n-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide Chemical compound C1[C@H](O)CCN1C1=NC=C(C(=O)NC=2C=CC(OC(F)(F)Cl)=CC=2)C=C1C1=CC=NN1 VOVZXURTCKPRDQ-CQSZACIVSA-N 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
GWUSZQUVEVMBPI-UHFFFAOYSA-N nimetazepam Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1 GWUSZQUVEVMBPI-UHFFFAOYSA-N 0.000 description 1
230000000422 nocturnal effect Effects 0.000 description 1
231100001160 nonlethal Toxicity 0.000 description 1
229940126578 oral vaccine Drugs 0.000 description 1
210000003254 palate Anatomy 0.000 description 1
210000002741 palatine tonsil Anatomy 0.000 description 1
230000001769 paralizing effect Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
201000000317 pneumocystosis Diseases 0.000 description 1
201000003144 pneumothorax Diseases 0.000 description 1
229960001539 poliomyelitis vaccine Drugs 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000005180 public health Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000011514 reflex Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
102220210367 rs55719932 Human genes 0.000 description 1
231100000817 safety factor Toxicity 0.000 description 1
208000008742 seborrheic dermatitis Diseases 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
238000010187 selection method Methods 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000011301 standard therapy Methods 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
208000006379 syphilis Diseases 0.000 description 1
SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
229940045145 uridine Drugs 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
244000000057 wild-type pathogen Species 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Microbiology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Mycology (AREA)
Biochemistry (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Plant Pathology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CA002085897A 1990-06-19 1991-06-19 Virus variant non pathogene Abandoned CA2085897A1 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US54052990A	1990-06-19	1990-06-19
US540,529		1990-06-19
US62595890A	1990-12-11	1990-12-11
US625,958		1990-12-11

Publications (1)

Publication Number	Publication Date
CA2085897A1 true CA2085897A1 (fr)	1991-12-20

Family

ID=27066463

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002085897A Abandoned CA2085897A1 (fr)	1990-06-19	1991-06-19	Virus variant non pathogene

Country Status (3)

Country	Link
EP (1)	EP0537247A4 (fr)
CA (1)	CA2085897A1 (fr)
WO (1)	WO1991019795A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6015661A (en) *	1994-02-14	2000-01-18	The Macfarlane Burnet Centre For Medical Research Limited	Methods for the detection of non-pathogenic HIV-1 strains containing deletions in the Nef coding region and U3 region of the LTR
AU699175B2 (en) *	1994-02-14	1998-11-26	Australian Red Cross Society (Nsw Division)	Non-pathogenic strains of HIV-1
IL112636A0 (en) *	1994-02-14	1995-05-26	Macfarlane Burnet Ctre Med Res	Non-pathogenic strains of hiv-1
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
TW200635607A (en)	2004-12-15	2006-10-16	Elan Pharm Inc	Humanized Aβ antibodies for use in improving cognition
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
PT2182983E (pt)	2007-07-27	2014-09-01	Janssen Alzheimer Immunotherap	Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL81568A0 (en) *	1986-02-14	1987-09-16	Us Commerce	Plasmids which inhibit human t-cell lymphotropic virus type iii replication
EP0242216A1 (fr) *	1986-04-16	1987-10-21	THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce	Clone non cytopathique de virus lymphotropique de T-cellule humaine type III
JPH01120284A (ja) *	1987-11-05	1989-05-12	Shiro Kato	Ｈｉｖ不完全粒子および該製造方法
IL89567A0 (en) *	1988-03-28	1989-09-10	Univ Leland Stanford Junior	Mutated hiv envelope protein
JPH02203783A (ja) *	1989-02-02	1990-08-13	Banyu Pharmaceut Co Ltd	抗原性を有する非感染性エイズウイルス産生クローン化ヒトｔ細胞

1991
- 1991-06-19 EP EP19910912526 patent/EP0537247A4/en not_active Withdrawn
- 1991-06-19 CA CA002085897A patent/CA2085897A1/fr not_active Abandoned
- 1991-06-19 WO PCT/US1991/004374 patent/WO1991019795A1/fr not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO1991019795A1 (fr)	1991-12-26
EP0537247A4 (en)	1993-09-08
EP0537247A1 (fr)	1993-04-21

Publication	Publication Date	Title
Pardy et al.	2017	Analysis of the T cell response to Zika virus and identification of a novel CD8+ T cell epitope in immunocompetent mice
Zhang et al.	1993	MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination
Rico-Hesse et al.	1998	Molecular evolution of dengue type 2 virus in Thailand
Schad et al.	1985	Predisposition to hookworm infection in humans
Martín et al.	2000	Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion
Dubbs et al.	1964	Mutant strains of herpes simplex deficient in thymidine kinase-inducing activity
Armstrong et al.	2003	Efficiency of dengue serotype 2 virus strains to infect and disseminate in Aedes aegypti
CA2085897A1 (fr)	1991-12-20	Virus variant non pathogene
Shioda et al.	1997	In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: association of V2 extension with slow disease progression
KR101150584B1 (ko)	2012-06-27	웨스트 나일 바이러스 백신
EA004921B1 (ru)	2004-10-28	Аттенуированный микроорганизм salmonella и способы его применения
Sciammas et al.	1999	TCRγδ cells and viruses
EP0510054A1 (fr)	1992-10-28	Fragments de la proteine du noyau de vih-1
Vickerman	1989	Trypanosome sociology and antigenic variation
JPH08504094A (ja)	1996-05-07	Ａ型肝炎ワクチン
Parvaneh et al.	2007	Vaccine-associated paralytic poliomyelitis in a patient with MHC class II deficiency
US5747526A (en)	1998-05-05	Anti-HIV /Aids Chemo(C)-, immuno(I)-, or ci-therapy using tur (or related compounds) and/or NVA (or EPV)
Mosa et al.	2009	Nonhematopoietic cells control the outcome of infection with Listeria monocytogenes in a nucleotide oligomerization domain 1-dependent manner
Zhan et al.	2022	Advancing a human onchocerciasis vaccine from antigen discovery to efficacy studies against natural infection of cattle with Onchocerca ochengi
Galler et al.	1998	Genetic variability among yellow fever virus 17D substrains
EP0491930A1 (fr)	1992-07-01	Vaccins prepares a partir d'un lentivirus de primate.
Jhancy	2024	Poxvirus Vaccines: Past, Present, and Future
SHISHIDO et al.	1958	The nature of immunity against scrub typhus in mice i. the resistance of mice, surviving subcutaneous infection of scrub typhus rickettsia, to intraperitoneal reinfection of the same agent
Turner	1973	Humoral and cellular immune responses of mice to rabies and smallpox vaccines
Locher et al.	1997	Superinfection with human immunodeficiency virus type 2 can reactivate virus production in baboons but is contained by a CD8 T cell antiviral response

Legal Events

Date	Code	Title	Description
1995-12-19	FZDE	Dead